{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:48:15Z","timestamp":1790826495512,"version":"4.1.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012513","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Cardiovasculares","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012513","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010198","name":"Ministerio de Econom\u00eda, Industria y Competitividad, Gobierno de Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012818","name":"Comunidad de Madrid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","revespcardiol.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.rec.2019.04.006","type":"journal-article","created":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T10:51:40Z","timestamp":1559904700000},"page":"853-862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Beta-blockers: Historical Perspective and Mechanisms of Action"],"prefix":"10.1016","volume":"72","author":[{"given":"Eduardo","family":"Oliver","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Mayor Jr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"D\u2019Ocon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rec.2019.04.006_bib0435","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0031-6997(24)01495-9","article-title":"Vascular adrenoceptors: an update","volume":"53","author":"Guimaraes","year":"2001","journal-title":"Pharmacol Rev."},{"key":"10.1016\/j.rec.2019.04.006_bib0440","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3389\/fphar.2018.00904","article-title":"New Insights in Cardiac beta-Adrenergic Signaling During Heart Failure and Aging","volume":"9","author":"De Lucia","year":"2018","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.rec.2019.04.006_bib0445","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1161\/CIRCRESAHA.118.311403","article-title":"G-Protein-Coupled Receptors in Heart Disease","volume":"123","author":"Wang","year":"2018","journal-title":"Circ Res."},{"key":"10.1016\/j.rec.2019.04.006_bib0450","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/415206a","article-title":"Seven-transmembrane-spanning receptors and heart function","volume":"415","author":"Rockman","year":"2002","journal-title":"Nature."},{"key":"10.1016\/j.rec.2019.04.006_bib0455","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1113\/jphysiol.1906.sp001148","article-title":"On some physiological actions of ergot","volume":"34","author":"Dale","year":"1906","journal-title":"J Physiol."},{"key":"10.1016\/j.rec.2019.04.006_bib0460","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1152\/ajplegacy.1948.153.3.586","article-title":"A study of the adrenotropic receptors","volume":"153","author":"Ahlquist","year":"1948","journal-title":"Am J Physiol."},{"key":"10.1016\/j.rec.2019.04.006_bib0465","first-page":"f47","article-title":"Pioneers in cardiology: Sir James Black, MB, ChB, FRS, FRCP. Interview by Mark Nicholls","volume":"117","author":"Black","year":"2008","journal-title":"Circulation."},{"key":"10.1016\/j.rec.2019.04.006_bib0470","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/214597a0","article-title":"Differentiation of receptor systems activated by sympathomimetic amines","volume":"214","author":"Lands","year":"1967","journal-title":"Nature."},{"key":"10.1016\/j.rec.2019.04.006_bib0475","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0031-6997(25)06780-8","article-title":"International Union of Pharmacology nomenclature of adrenoceptors","volume":"46","author":"Bylund","year":"1994","journal-title":"Pharmacol Rev."},{"key":"10.1016\/j.rec.2019.04.006_bib0480","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1126\/science.2570461","article-title":"Molecular characterization of the human beta 3-adrenergic receptor","volume":"245","author":"Emorine","year":"1989","journal-title":"Science."},{"key":"10.1016\/j.rec.2019.04.006_bib0485","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/309163a0","article-title":"Atypical beta-adrenoceptor on brown adipocytes as target for anti-obesity drugs","volume":"309","author":"Arch","year":"1984","journal-title":"Nature."},{"key":"10.1016\/j.rec.2019.04.006_bib0490","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.cell.2012.11.015","article-title":"G-protein-coupled receptors signal victory","volume":"151","author":"Benovic","year":"2012","journal-title":"Cell."},{"key":"10.1016\/j.rec.2019.04.006_bib0495","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0022-3565(25)12519-6","article-title":"Adrenergic blockade of the mammalian heart by a dichloro analogue of isoproterenol","volume":"124","author":"Moran","year":"1958","journal-title":"J. Pharm Exp Ther."},{"key":"10.1016\/j.rec.2019.04.006_bib0500","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1017\/S0025727300009455","article-title":"Putting Theory into Practice: James Black, Receptor Theory and the Development of the Beta-Blockers at ICI, 1958-1978","volume":"50","author":"Quirke","year":"2006","journal-title":"Medical History."},{"key":"10.1016\/j.rec.2019.04.006_bib0505","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.tips.2011.02.010","article-title":"Evolution of \u03b2-blockers: from anti-anginal drugs to ligand-directed signalling","volume":"32","author":"Baker","year":"2011","journal-title":"Trends Pharmacol Sci."},{"key":"10.1016\/j.rec.2019.04.006_bib0510","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00210-003-0860-y","article-title":"Comparative pharmacology of human beta-adrenergic receptor subtypes-characterization of stably transfected receptors in CHO cells","volume":"369","author":"Hoffmann","year":"2004","journal-title":"Naunyn Schmiedebergs Arch Pharmacol."},{"key":"10.1016\/j.rec.2019.04.006_bib0515","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/j.1476-5381.2010.00754.x","article-title":"The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors","volume":"160","author":"Baker","year":"2010","journal-title":"Br J Pharmacol."},{"key":"10.1016\/j.rec.2019.04.006_bib0520","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejphar.2010.11.036","article-title":"Lack of evidence that nebivolol is a \u03b23-adrenoceptor agonist","volume":"654","author":"Frazier","year":"2011","journal-title":"Eur J Pharmacol."},{"key":"10.1016\/j.rec.2019.04.006_bib0525","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1755-5922.2008.00054.x","article-title":"Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide","volume":"26","author":"Gupta","year":"2008","journal-title":"Cardiovasc Ther."},{"key":"10.1016\/j.rec.2019.04.006_bib0530","doi-asserted-by":"crossref","first-page":"14555","DOI":"10.1073\/pnas.0804745105","article-title":"Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation","volume":"105","author":"Kim","year":"2008","journal-title":"Proc Natl Acad Sci USA."},{"key":"10.1016\/j.rec.2019.04.006_bib0535","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0026-895X(25)10022-9","article-title":"Inverse agonist activity of beta-adrenergic antagonists","volume":"45","author":"Chidiac","year":"1994","journal-title":"Mol Pharmacol."},{"key":"10.1016\/j.rec.2019.04.006_bib0540","doi-asserted-by":"crossref","first-page":"16657","DOI":"10.1073\/pnas.0707936104","article-title":"A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signalling","volume":"104","author":"Wisler","year":"2007","journal-title":"Proc Natl Acad Sci USA."},{"key":"10.1016\/j.rec.2019.04.006_bib0545","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1124\/mol.64.6.1357","article-title":"Agonist and inverse agonist actions of beta-blockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signalling","volume":"64","author":"Baker","year":"2003","journal-title":"Mol Pharmacol."},{"key":"10.1016\/j.rec.2019.04.006_bib0550","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1124\/mol.106.026716","article-title":"Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy","volume":"70","author":"Galandrin","year":"2006","journal-title":"Mol Pharmacol."},{"key":"10.1016\/j.rec.2019.04.006_bib0555","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.bjp.0701600","article-title":"Efficacy of inverse agonists in cells overexpressing a constitutively active beta2-adrenoceptor and type II adenylyl cyclase","volume":"123","author":"Stevens","year":"1998","journal-title":"Br J Pharmacol."},{"key":"10.1016\/j.rec.2019.04.006_bib0560","doi-asserted-by":"crossref","first-page":"11406","DOI":"10.1073\/pnas.1936664100","article-title":"Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors","volume":"100","author":"Azzi","year":"2003","journal-title":"Proc Natl Acad Sci USA."},{"key":"10.1016\/j.rec.2019.04.006_bib0565","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1527-3466.2001.tb00062.x","article-title":"Sotalol: the mechanism of its antiarrhythmic-defibrillating effect","volume":"19","author":"Manoach","year":"2001","journal-title":"Cardiovasc Drug Rev."},{"key":"10.1016\/j.rec.2019.04.006_bib0570","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1096\/fj.11-192435","article-title":"Predicting in vivo cardiovascular properties of \u03b2-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses","volume":"25","author":"Baker","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/j.rec.2019.04.006_bib0575","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41467-017-01855-z","article-title":"Galphai is required for carvedilol-induced beta1 adrenergic receptor beta-arrestin biased signaling","volume":"8","author":"Wang","year":"2017","journal-title":"Nat Commun."},{"issue":"9A","key":"10.1016\/j.rec.2019.04.006_bib0580","doi-asserted-by":"crossref","first-page":"3B","DOI":"10.1016\/j.amjcard.2004.01.003","article-title":"Pharmacology of carvedilol","volume":"93","author":"Dulin","year":"2004","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.rec.2019.04.006_bib0585","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1476-5381.1991.tb12513.x","article-title":"The alpha- and beta-adrenoceptor blocking activities of labetalol and its RR-SR (50:50) stereoisomers","volume":"104","author":"Riva","year":"1991","journal-title":"Br J Pharmacol."},{"key":"10.1016\/j.rec.2019.04.006_bib0590","doi-asserted-by":"crossref","first-page":"e71980","DOI":"10.1371\/journal.pone.0071980","article-title":"The \u03b2-blocker nebivolol is a GRK\/\u03b2-arrestin biased agonist","volume":"8","author":"Erickson","year":"2013","journal-title":"PLoS One."},{"key":"10.1016\/j.rec.2019.04.006_bib0595","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00210-006-0125-7","article-title":"\u03b2-adrenoceptor blocker treatment and the cardiac \u03b2-adrenoceptor-G-protein(s)-adenylyl cyclase system in chronic heart failure","volume":"374","author":"Brodde","year":"2007","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol."},{"key":"10.1016\/j.rec.2019.04.006_bib0600","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.amjmed.2008.06.025","article-title":"Fifty years of beta-adrenergic blockade: a golden era in clinical medicine and molecular pharmacology","volume":"121","author":"Frishman","year":"2008","journal-title":"Am J Med."},{"key":"10.1016\/j.rec.2019.04.006_bib0605","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/1573402114666180918102735","article-title":"Three generations of \u03b2-blockers: history, class differences and clinical applicability","volume":"15","author":"Do Vale","year":"2019","journal-title":"Curr Hypertens Rev."},{"key":"10.1016\/j.rec.2019.04.006_bib0610","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1185\/03007990903533681","article-title":"Effects of \u03b2-blockers on glucose and lipid metabolism","volume":"26","author":"Fonseca","year":"2010","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.rec.2019.04.006_bib0615","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/978-3-642-38664-0_21","article-title":"Pulmonary hypertension: old targets revisited (statins, PPARs, beta-blockers)","volume":"218","author":"Watson","year":"2013","journal-title":"Handb Exp Pharmacol."},{"key":"10.1016\/j.rec.2019.04.006_bib0620","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1476-5381.2010.00727.x","article-title":"The complex G protein-coupled receptor kinase 2 (GRK2) interactome unveils new physiopathological targets","volume":"160","author":"Penela","year":"2010","journal-title":"Br J Pharmacol."},{"key":"10.1016\/j.rec.2019.04.006_bib0625","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cellsig.2017.04.002","article-title":"G protein-coupled receptor kinase 2 (GRK2) as an integrative signalling node in the regulation of cardiovascular function and metabolic homeostasis","volume":"41","author":"Mayor","year":"2018","journal-title":"Cell Signal."},{"key":"10.1016\/j.rec.2019.04.006_bib0630","doi-asserted-by":"crossref","first-page":"8969","DOI":"10.1074\/jbc.R115.713313","article-title":"The beta-Arrestins: Multifunctional Regulators of G Protein-coupled Receptors","volume":"291","author":"Smith","year":"2016","journal-title":"J Biol Chem."},{"key":"10.1016\/j.rec.2019.04.006_bib0635","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1161\/CIRCRESAHA.117.310520","article-title":"Adrenergic Receptors in Individual Ventricular Myocytes: The Beta-1 and Alpha-1B Are in All Cells, the Alpha-1A Is in a Subpopulation, and the Beta-2 and Beta-3 Are Mostly Absent","volume":"120","author":"Myagmar","year":"2017","journal-title":"Circ Res."},{"key":"10.1016\/j.rec.2019.04.006_bib0640","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3389\/fphar.2015.00203","article-title":"Cardiac cAMP: production, hydrolysis, modulation and detection","volume":"6","author":"Boularan","year":"2015","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.rec.2019.04.006_bib0645","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.1113\/JP271965","article-title":"Calcium\/calmodulin-dependent kinase II and nitric oxide synthase 1-dependent modulation of ryanodine receptors during beta-adrenergic stimulation is restricted to the dyadic cleft","volume":"594","author":"Dries ESantiago","year":"2016","journal-title":"J Physiol."},{"key":"10.1016\/j.rec.2019.04.006_bib0650","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.3389\/fphys.2018.01453","article-title":"Arrhythmogenic Mechanisms in Heart Failure: Linking \u03b2-Adrenergic Stimulation","volume":"9","author":"Johnson","year":"2018","journal-title":"Stretch, and Calcium. Front Physiol."},{"key":"10.1016\/j.rec.2019.04.006_bib0655","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1126\/science.1185988","article-title":"Beta2-adrenergic receptor redistribution in heart failure changes cAMP compartmentation","volume":"327","author":"Nikolaev","year":"2010","journal-title":"Science."},{"key":"10.1016\/j.rec.2019.04.006_bib0660","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.1091\/mbc.e06-05-0422","article-title":"Association of 14-3-3 proteins to beta1-adrenergic receptors modulates Kv11.1 K+channel activity in recombinant systems","volume":"17","author":"Tutor","year":"2006","journal-title":"Mol Biol Cell."},{"key":"10.1016\/j.rec.2019.04.006_bib0665","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cardiores.2005.09.011","article-title":"Mechanisms of regulation of G protein-coupled receptor kinases (GRKs) and cardiovascular disease","volume":"69","author":"Penela","year":"2006","journal-title":"Cardiovasc Res."},{"key":"10.1016\/j.rec.2019.04.006_bib0670","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.3389\/fphar.2018.01336","article-title":"Therapeutic Targets for Treatment of Heart Failure: Focus on GRKs and beta-Arrestins Affecting betaAR Signaling","volume":"9","author":"Mangmool","year":"2018","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.rec.2019.04.006_bib0675","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1172\/JCI31901","article-title":"Beta arrestin-mediated \u03b21 adrenergic receptor transactivation of the EGFR confers cardioprotection","volume":"117","author":"Noma","year":"2007","journal-title":"J Clin Invest."},{"key":"10.1016\/j.rec.2019.04.006_bib0680","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/CIRCRESAHA.114.302766","article-title":"Beta-arrestin1-biased beta1-adrenergic receptor signaling regulates microRNA processing","volume":"114","author":"Kim","year":"2014","journal-title":"Circ Res."},{"key":"10.1016\/j.rec.2019.04.006_bib0685","article-title":"Epac Function and cAMP Scaffolds in the Heart and Lung","author":"Laudette","year":"2018","journal-title":"J Cardiovasc Dev Dis."},{"key":"10.1016\/j.rec.2019.04.006_bib0690","doi-asserted-by":"crossref","first-page":"H368","DOI":"10.1152\/ajpheart.01061.2011","article-title":"Different expression of adrenoceptors and GRKs in the human myocardium depends on heart failure etiology and correlates to clinical variables","volume":"303","author":"Monto","year":"2012","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"10.1016\/j.rec.2019.04.006_bib0695","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1161\/01.RES.0000250046.69918.d5","article-title":"Cyclic AMP imaging in adult cardiac myocytes reveals far-reaching beta1-adrenergic but locally confined beta2-adrenergic receptor-mediated signaling","volume":"99","author":"Nikolaev","year":"2006","journal-title":"Circ Res."},{"key":"10.1016\/j.rec.2019.04.006_bib0700","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.yjmcc.2011.01.012","article-title":"CaMKII in myocardial hypertrophy and heart failure","volume":"51","author":"Anderson","year":"2011","journal-title":"J Mol Cell Cardiol."},{"key":"10.1016\/j.rec.2019.04.006_bib0705","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jacbts.2018.06.002","article-title":"Carvedilol Prevents Redox Inactivation of Cardiomyocyte Beta1-Adrenergic Receptors","volume":"3","author":"Park","year":"2018","journal-title":"JACC Basic Transl Sci."},{"key":"10.1016\/j.rec.2019.04.006_bib0710","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.molcel.2018.03.034","article-title":"S-Nitrosylation of beta-Arrestins Biases Receptor Signaling and Confers Ligand Independence","volume":"70","author":"Hayashi","year":"2018","journal-title":"Mol Cell."},{"key":"10.1016\/j.rec.2019.04.006_bib0715","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cardiores.2007.05.022","article-title":"Anti-beta1-adrenergic receptor autoantibodies are potent stimulators of the ERK1\/2 pathway in cardiac cells","volume":"76","author":"Tutor","year":"2007","journal-title":"Cardiovasc Res."},{"key":"10.1016\/j.rec.2019.04.006_bib0720","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jacc.2017.05.020","article-title":"Beta1-Blockade Prevents Post-Ischemic Myocardial Decompensation Via beta3AR-Dependent Protective Sphingosine-1 Phosphate Signaling","volume":"70","author":"Cannavo","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.rec.2019.04.006_bib0725","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1161\/CIRCULATIONAHA.110.988642","article-title":"G protein-coupled receptor kinase 2 activity impairs cardiac glucose uptake and promotes insulin resistance after myocardial ischemia","volume":"123","author":"Ciccarelli","year":"2011","journal-title":"Circulation."},{"key":"10.1016\/j.rec.2019.04.006_bib0730","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.semcancer.2017.04.013","article-title":"G protein-coupled receptor kinases (GRKs) in tumorigenesis and cancer progression: GPCR regulators and signaling hubs","volume":"48","author":"Nogues","year":"2018","journal-title":"Semin Cancer Biol."},{"issue":"12 Pt A","key":"10.1016\/j.rec.2019.04.006_bib0735","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1016\/j.bbadis.2014.09.004","article-title":"Downregulation of G protein-coupled receptor kinase 2 levels enhances cardiac insulin sensitivity and switches on cardioprotective gene expression patterns","volume":"1842","author":"Lucas","year":"2014","journal-title":"Biochim Biophys Acta."},{"key":"10.1016\/j.rec.2019.04.006_bib0740","doi-asserted-by":"crossref","first-page":"ra73","DOI":"10.1126\/scisignal.aaa4374","article-title":"Reversal of diet-induced obesity and insulin resistance by inducible genetic ablation of GRK2","volume":"8","author":"Vila-Bedmar","year":"2015","journal-title":"Sci Signal."},{"key":"10.1016\/j.rec.2019.04.006_bib0745","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12933-016-0474-6","article-title":"Obesity-induced cardiac lipid accumulation in adult mice is modulated by G protein-coupled receptor kinase 2 levels","volume":"15","author":"Lucas","year":"2016","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.rec.2019.04.006_bib0750","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.tem.2017.02.002","article-title":"Insulin and beta Adrenergic Receptor Signaling: Crosstalk in Heart","volume":"28","author":"Fu","year":"2017","journal-title":"Trends Endocrinol Metab."},{"key":"10.1016\/j.rec.2019.04.006_bib0755","doi-asserted-by":"crossref","first-page":"32116","DOI":"10.1074\/jbc.M204895200","article-title":"Beta-adrenergic receptor-mediated DNA synthesis in cardiac fibroblasts is dependent on transactivation of the epidermal growth factor receptor and subsequent activation of extracellular signal-regulated kinases","volume":"277","author":"Kim","year":"2002","journal-title":"J Biol Chem."},{"key":"10.1016\/j.rec.2019.04.006_bib0760","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.bbadis.2010.07.003","article-title":"Beta(2)-adrenergic receptor regulates cardiac fibroblast autophagy and collagen degradation","volume":"1812","author":"Aranguiz-Urroz","year":"2011","journal-title":"Biochim Biophys Acta."},{"key":"10.1016\/j.rec.2019.04.006_bib0765","doi-asserted-by":"crossref","first-page":"14780","DOI":"10.1038\/ncomms14780","article-title":"Neutrophil stunning by metoprolol reduces infarct size","volume":"8","author":"Garcia-Prieto","year":"2017","journal-title":"Nat Commun."},{"issue":"5 Suppl","key":"10.1016\/j.rec.2019.04.006_bib0770","first-page":"S9","article-title":"Contemporary use of \u03b2-blockers: clinical relevance of subclassification","volume":"30","author":"Poirier","year":"2014","journal-title":"Can J Cardiol."},{"key":"10.1016\/j.rec.2019.04.006_bib0775","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/bph.12121","article-title":"Different \u03b2-adrenoceptor subtypes coupling to cAMP or NO\/cGMP pathways: implications in the relaxant response of rat conductance and resistance vessels","volume":"169","author":"Flacco","year":"2013","journal-title":"Br J Pharmacol."},{"key":"10.1016\/j.rec.2019.04.006_bib0780","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/ijnp\/pyy071","article-title":"Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity","volume":"21","author":"Berg","year":"2018","journal-title":"Int J Neuropsychopharmacol."},{"key":"10.1016\/j.rec.2019.04.006_bib0785","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0165-6147(97)90685-4","article-title":"Inverse agonism and the regulation of receptor number","volume":"18","author":"Milligan","year":"1997","journal-title":"Trends Pharmacol Sci."},{"key":"10.1016\/j.rec.2019.04.006_bib0790","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/S0026-895X(25)09605-1","article-title":"Inverse agonist-induced up-regulation of the human beta2-adrenoceptor in transfected neuroblastoma X glioma hybrid cells","volume":"50","author":"MacEwan","year":"1996","journal-title":"Mol Pharmacol."},{"key":"10.1016\/j.rec.2019.04.006_bib0795","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/0735-1097(95)00425-4","article-title":"Analysis of beta-adrenergic receptor mRNA levels in human ventricular biopsy specimens by quantitative polymerase chain reactions: progressive reduction of beta 1-adrenergic receptor mRNA in heart failure","volume":"27","author":"Engelhardt","year":"1996","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.rec.2019.04.006_bib0800","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1751-7176.2011.00515.x","article-title":"Beta-Adrenergic Blockers","volume":"13","author":"Frishman","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.rec.2019.04.006_bib0805","doi-asserted-by":"crossref","first-page":"5444","DOI":"10.1111\/bph.12965","article-title":"Biased \u03b22-adrenoceptor signalling in heart failure: pathophysiology and drug discovery","volume":"172","author":"Woo","year":"2015","journal-title":"Br J Pharmacol."},{"key":"10.1016\/j.rec.2019.04.006_bib0810","first-page":"247","volume":"25","author":"Nawarskas","year":"2017","journal-title":"Celiprolol a unique selective adrenoceptor modulator Cardiol Rev."},{"key":"10.1016\/j.rec.2019.04.006_bib0815","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.pharmthera.2005.12.002","article-title":"Beta3-adrenoceptors in the cardiovascular system: putative roles in human pathologies","volume":"111","author":"Rozec","year":"2006","journal-title":"Pharmacol Ther."},{"key":"10.1016\/j.rec.2019.04.006_bib0820","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1476-5381.2009.00074.x","article-title":"Investigation of the different adrenoceptor targets of nebivolol enantiomers in rat thoracic aorta","volume":"156","author":"Tran Quang","year":"2009","journal-title":"Br J Pharmacol."},{"key":"10.1016\/j.rec.2019.04.006_bib0825","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3109\/10641963.2015.1081233","article-title":"Nebivolol ameliorates asymmetric dimethylarginine-induced vascular response in rat aorta via \u03b23 adrenoceptor-mediated mechanism","volume":"38","author":"Wang","year":"2016","journal-title":"Clin Exp Hypertens."},{"key":"10.1016\/j.rec.2019.04.006_bib0830","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.jacc.2008.11.057","article-title":"Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart","volume":"53","author":"Rozec","year":"2008","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.rec.2019.04.006_bib0835","doi-asserted-by":"crossref","first-page":"e98179","DOI":"10.1371\/journal.pone.0098179","article-title":"Nebivolol Protects against myocardial Infarction Injury via Stimulation of Beta 3-Adrenergic Receptors and Nitric Oxide Signaling","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS One."},{"key":"10.1016\/j.rec.2019.04.006_bib0840","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00395-016-0567-0","article-title":"Beta-3 adrenergic agonists reduce pulmonary vascular resistance and improve right ventricular performance in a porcine model of chronic pulmonary hypertension","volume":"111","author":"Garc\u00eda-\u00c1lvarez","year":"2016","journal-title":"Basic Res Cardiol."},{"issue":"Pt B","key":"10.1016\/j.rec.2019.04.006_bib0845","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.biocel.2016.04.009","article-title":"Delineating biased ligand efficacy at 7TM receptors from an experimental perspective","volume":"77","author":"Galandrin","year":"2016","journal-title":"Int J Biochem Cell Biol."},{"key":"10.1016\/j.rec.2019.04.006_bib0850","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1124\/jpet.115.227959","article-title":"Recruitment of \u03b2-arrestin 1 and 2 to the \u03b22-adrenoceptor: analysis of 65 ligands","volume":"355","author":"Littmann","year":"2015","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1016\/j.rec.2019.04.006_bib0855","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.coph.2012.12.002","article-title":"Beta blockers, nitric oxide and cardiovascular disease","volume":"13","author":"Vanhoutte","year":"2013","journal-title":"Curr Opin Pharmacol."},{"key":"10.1016\/j.rec.2019.04.006_bib0860","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.amjhyper.2005.11.011","article-title":"Carvedilol action is dependent on endogenous production of nitric oxide","volume":"19","author":"Afonso","year":"2006","journal-title":"Am J Hypertens."}],"container-title":["Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1885585719301100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1885585719301100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:56:43Z","timestamp":1761821803000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1885585719301100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":86,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1885585719301100"],"URL":"https:\/\/doi.org\/10.1016\/j.rec.2019.04.006","relation":{},"ISSN":["1885-5857"],"issn-type":[{"value":"1885-5857","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beta-blockers: Historical Perspective and Mechanisms of Action","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rec.2019.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.rec.2019.04.014","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Sociedad Espa\u00f1ola de Cardiolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}